Vadivel Ganapathy

Vadivel Ganapathy, Ph.D., is a Professor in the Department of Cell Biology and Biochemistry at the School of Medicine, Texas Tech University Health Sciences Center (TTUHSC) in Lubbock, Texas. His research integrates molecular mechanisms of disease with translational therapeutic development across cancer biology, microbiome interactions, and retinal pathophysiology.

Education

• Ph.D. in Biochemistry, University of Madras, India

Research Focus

Dr. Ganapathy's program centers on four pillars: (1) Targeting amino acid transporters like SLC6A14 for novel anticancer therapies in colon, pancreatic, and breast cancers; (2) Elucidating gut microbiome-host communication via short-chain fatty acid transporters (SLC5A8) and receptors (GPR109A/GPR43) in colonic inflammation and carcinogenesis; (3) Investigating hemochromatosis-driven cancer progression through iron overload mechanisms; and (4) Studying retinal iron homeostasis in diabetic retinopathy and macular degeneration. His approach combines molecular biology, metabolomics, and animal models to identify druggable targets.

Publication Trends

Analysis of 15 recent publications (2024-2025) reveals intensifying focus on transporter-targeted nanomedicine for cancer therapy, particularly SLC6A14/SLC38A5 inhibition in glutamine-addicted tumors. Significant work explores microbiome-derived metabolites (butyrate, ketones) in colitis-cancer axis regulation and iron dysregulation in diabetic complications. Emerging themes include ferroptosis induction via transporter blockade and GPR109A-mediated tumor suppression through p53 activation.

Research Infrastructure

Dr. Ganapathy leads an active laboratory at TTUHSC investigating nutrient transporter biology across disease contexts. His team employs CRISPR, metabolomics, and transgenic mouse models to develop therapeutic strategies targeting cancer metabolism, microbiome-host interfaces, and retinal iron pathology, with recent emphasis on nanoparticle-based drug delivery systems.